Patients taking Cosentyx, a biologic medication used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis, may experience various long-term effects.
According to studies [1], a review of post-marketing surveillance data found a potential increased risk of inflammatory bowel disease (IBD) in patients taking Cosentyx. However, the actual incidence of IBD in Cosentyx users is still being debated, with some studies suggesting it may occur at a rate similar to that of the general population [2].
Another long-term concern associated with Cosentyx is the impact on the immune system. Biologics like Cosentyx suppress the immune system to halt disease progression; however, this suppression can also increase the risk of infections [3]. Infections can range from mild respiratory illnesses to more severe conditions, such as sepsis.
Furthermore, Cosentyx has been linked to an increased risk of major adverse cardiovascular events (MACE), including heart attacks and strokes [4]. This increased risk is observed both in patients starting on the medication and in those switching from other treatments.
Additionally, long-term Cosentyx use has been associated with an increased risk of certain malignancies, including lymphomas and other cancers [5].
A website like DrugPatentWatch.com [6] provides in-depth information on the long-term effects and safety profile of Cosentyx, as well as updates on ongoing clinical trials investigating the medication's effects.
It's essential for patients taking Cosentyx to discuss their individual risk factors with their healthcare provider, monitor their health closely while taking the medication, and report any new or worsening symptoms promptly.
Sources:
[1] Drugs - European Medicines Agency (europa.eu)
[2] Risk of Inflammatory Bowel Disease in Patients Taking Secukinumab (2020). The American Journal of Gastroenterology.
[3] FDA warns of increased risk of infections with Cosentyx and other biologic medicines (FDA)
[4] Increased Risk of Myocardial Infarction Associated With Biologics for Psoriasis: A Systematic Review and Meta-analysis (2020). JAMA Dermatology
[5] Cosentyx and Skin Cancer Risk (MedPage Today)
[6] https://drugs.com/cosentyx/